FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

堆栈库

Natural GH Pulse

GH Optimizationbeginner

90

协同作用

90
Share
肽类

2

平均每日mcg

300

级别

beginner

添加时间

May 17, 2026

概述

The Natural GH Pulse stack combines a growth hormone releasing hormone (GHRH) analog with a selective growth hormone secretagogue to produce amplified, pulsatile GH release that mimics the body''s natural rhythm. CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF) is a truncated and modified analog of endogenous GHRH that stimulates the pituitary to produce growth hormone. Its short half-life (approximately 30 minutes) means it generates discrete GH pulses rather than sustained elevation, preserving the body''s natural feedback mechanisms. Ipamorelin is a pentapeptide that selectively activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, triggering GH release without significantly affecting cortisol, prolactin, or ACTH levels — making it the cleanest growth hormone secretagogue available. Unlike older secretagogues such as GHRP-6, Ipamorelin does not stimulate appetite or raise cortisol, making it suitable for long-term use. The synergy between CJC-1295 (no DAC) and Ipamorelin is well-documented: GHRH analogs and ghrelin-mimetics act through different receptors on the same pituitary cells, producing an amplified GH pulse approximately 3-5x greater than either peptide alone. This phenomenon is called the "GH synergy effect" and has been demonstrated in human clinical studies. The combined pulse mimics the magnitude of youthful GH secretion while maintaining pulsatility, which is critical for avoiding GH receptor desensitization. Benefits include improved sleep architecture (deeper slow-wave sleep), enhanced recovery from exercise, modest fat reduction, and improved skin quality over 3-6 months of consistent use.

给药方案

CJC-1295 (no DAC)

Every day· subcutaneous

了解更多关于CJC-1295 (no DAC) →

100 mcg

每剂

Ipamorelin

Every day· subcutaneous

了解更多关于Ipamorelin →

200 mcg

每剂

目标与证据

Growth hormoneAnti-agingFat lossSleep qualityRecovery
证据等级:人体临床试验

警告

  • CJC-1295 and Ipamorelin both remain on the FDA Category 2 restricted-compounding list as of July 2026. Do not use with active cancer.

Comments

Sign in to join the discussion

免责声明: 此堆栈由社区提交,仅供研究用途。Peptide Contacts不对提交的堆栈的安全性或有效性进行验证。使用任何肽类协议前,请务必咨询合格的医疗专业人员。